This activity features presentations and downloadable slide decks highlighting the most recent data on acute myeloid leukemia.
1.5 AMA PRA Category 1 Credit(s)™
Jun 21, 2019
Jun 21, 2020
Abstract #PF293: Phase 3 exploratory analysis of outcomes in older adults with newly diagnosed, high-risk/secondary AML who achieved remission with CPX-351 versus 7+3 induction
Featured Expert: Jorge Cortes, MD
Abstract #PS1029: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase 2 randomized trial
Featured Expert: Michael Heuser, MD
Abstract #PS1035: Gemtuzumab ozogamicine-based salvage therapies in refractory/relapsed acute myeloid leukemia patients
Featured Expert: Sonia Jaramillo Segura, MD, PhD
Abstract #S876: Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated (FLT3MUT+) relapsed/refractory (R/R) acute myeloid leukemia (AML): results from the phase 3 ADMIRAL trial
Featured Expert: Mark J. Levis, MD, PhD
Abstract #S879: Results of ASTRAL-1 study, a phase 3 randomized trial of guadecitabine (G) vs treatment choice (TC) in treatment naïve acute myeloid leukemia (TN-AML) not eligible for intensive chemotherapy (IC)
Featured Expert: Elias Jabbour, MD
Abstract #S880: A phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukemia (AML)
Featured Expert: Walter Fiedler, MD
Jorge Cortes, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Walter Fiedler, MDUniversity Medical Center Hamburg-Eppendorf
Michael Heuser, MDHannover Medical School
Elias Jabbour, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Mark J. Levis, MD, PhDSidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland, United States
Sonia Jaramillo Segura, MD, PhDHeidelberg University Hospital
This activity is designed for hematologists/oncologists who manage patients with AML.
Upon completion of this activity, participants will:
- Have increased knowledge regarding the key data about acute myeloid leukemia from the conference
- Have greater competence related to applying key data from the conference to clinical practice, as appropriate for patients with acute myeloid leukemia
This educational activity is supported by a grant from Jazz Pharmaceuticals.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1.5 hours
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Cortes has disclosed that he has received consulting fees from Astellas, BMS, Daiichi, Jazz, Novartis, Pfizer, and Takeda. He has also disclosed performance of contracted research (paid to his institution) for Astellas, BMS, Daiichi, Jazz, Novartis, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Fiedler has disclosed that he has received consulting fees from Amgen, Ariad/Incyte, Jazz Pharmaceuticals, Novartis, and Pfizer. He has also disclosed fees for contracted research for Amgen. He has disclosed meeting attendance for Amgen, Daiichi Sankyo, Jazz, and Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Heuser has disclosed that he has received consulting fees from Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Jabbour has disclosed research grants from and advisory roles for Abbvie, Adaptive, Amgen, BMS, Pfizer, and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Levis has disclosed that he has received consulting fees from Amgen, Agios, Astellas, Daiichi, and Novartis. He has also disclosed fees for contracted research from Astellas, Daiichi, Fujifilm, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Segura has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed no relevant financial relationships.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.